{"analyses":[{"ciLowerLimit":"-0.0075","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.2136","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0677","paramType":"Slope","paramValue":"0.1031","statisticalComment":"degrees of freedom: 4516","statisticalMethod":"ANOVA","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.24","value":"5.14"},{"groupId":"OG001","spread":"2.56","value":"5.03"}]}]}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"1103"},{"groupId":"OG001","value":"323"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"4619"},{"groupId":"OG001","value":"1323"}],"units":"cycles"}],"description":"Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery.","dispersionType":"Standard Deviation","groups":[{"description":"Cancer patients with solid tumor treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006: Solid Tumor"},{"description":"Cancer patients with hematological tumor treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG001","title":"EP2006: Hematological Tumor"}],"paramType":"MEAN","populationDescription":"Evaluable sample by tumor type with data","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"EP2006 Duration by Tumor Type: Cycle Level","type":"PRIMARY","typeUnitsAnalyzed":"cycles","unitOfMeasure":"days"}